Merck, operating as MSD outside the US and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, have entered into a global licensing agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist. Under the terms of the agreement,
Merck, the science and technology company, has announced a €70 million investment to expand its Bioconjugation Center of Excellence in St. Louis, Missouri, USA. This development will triple the site’s capacity, supporting bioconjugate drug production for clients worldwide. The company’s
Merck has completed the acquisition of Modifi Bio, a startup developed from Yale University, for an upfront payment of $30 million. The deal could ultimately be worth up to $1.3 billion, depending on future milestone payments associated with the company’s
Merck, has been awarded the EXCiPACT cGMP (current Good Manufacturing Practice) certification for Pharmaceutical Auxiliary Materials (PAMs) across its global Cell Culture Media (CCM) production sites. This certification is significant as it marks the first time a company in the
Merck, a global player in the life science sector, has announced the opening of its expanded distribution center in Schnelldorf, Germany. The expansion, which cost €180 million, added 25,000 square meters to the site, almost doubling its size. The site
Merck is a leading science and technology company providing solutions to help advance the promise of life saving therapies. Merck is a leader in life science. With our Millipore® CTDMO Services we simplify bringing life-changing molecules to market, across multiple modalities like
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
